ACETAZOLAMIDE IN DOMINANT CYSTOID MACULAR DYSTROPHY - A PILOT-STUDY

Eight patients (four men, four women), with low visual acuity caused b y autosomal dominant cystoid macular dystrophy, were treated daily wit h oral 250 mg dose acetazolamide. Treatment ranged from two to 17 mont hs. None of these eight patients had improvement of visual acuity of m ore than 0. 1. Conclusion: Treatment with 250 mg acetazolamide appears not to be an effective therapy for cystoid macular oedema in dominant cystoid macular dystrophy. The electroretinography b-wave/a-wave rati o was normal. The primary lesion in dominant cystoid macular dystrophy remains obscure.